Literature DB >> 28465341

Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.

Francesca Gorini1, Laura Azzimonti2, Gloria Delfanti1, Lydia Scarfò3,4, Cristina Scielzo3, Maria Teresa Bertilaccio3,5, Pamela Ranghetti3, Alessandro Gulino6, Claudio Doglioni4,7, Arianna Di Napoli8, Miriam Capri9, Claudio Franceschi9, Federico Caligaris-Cappio3,4, Paolo Ghia3,4, Matteo Bellone1, Paolo Dellabona1, Giulia Casorati1, Claudia de Lalla1.   

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by the expansion of malignant CD5+ B lymphocytes in blood, bone marrow, and lymphoid organs. CD1d-restricted invariant natural killer T (iNKT) cells are innate-like T lymphocytes strongly implicated in tumor surveillance. We investigated the impact of iNKT cells in the natural history of the disease in the Eμ-Tcl1 (Tcl1) CLL mouse model and 68 CLL patients. We found that Tcl1-CLL cells express CD1d and that iNKT cells critically delay disease onset but become functionally impaired upon disease progression. In patients, disease progression correlates with high CD1d expression on CLL cells and impaired iNKT cells. Conversely, disease stability correlates with negative or low CD1d expression on CLL cells and normal iNKT cells, suggesting indirect leukemia control. iNKT cells indeed hinder CLL survival in vitro by restraining CD1d-expressing nurse-like cells, a relevant proleukemia macrophage population. Multivariable analysis identified iNKT cell frequency as an independent predictor of disease progression. Together, these results support the contribution of iNKT cells to CLL immune surveillance and highlight iNKT cell frequency as a prognostic marker for disease progression.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28465341     DOI: 10.1182/blood-2016-11-751065

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma.

Authors:  Laura Escribà-Garcia; Carmen Alvarez-Fernández; Ana Carolina Caballero; Robert Schaub; Jorge Sierra; Javier Briones
Journal:  Oncoimmunology       Date:  2018-11-26       Impact factor: 8.110

2.  Impacts of the MHC class I-like XNC10 and innate-like T cells on tumor tolerance and rejection in the amphibian Xenopus.

Authors:  Maureen Banach; Eva-Stina Edholm; Xavier Gonzalez; Abdellatif Benraiss; Jacques Robert
Journal:  Carcinogenesis       Date:  2019-07-20       Impact factor: 4.944

3.  Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16+ Oral Tumors and Immunologic Control.

Authors:  Yi-Hsin Lin; Ming-Chieh Yang; Ssu-Hsueh Tseng; Rosie Jiang; Andrew Yang; Emily Farmer; Shiwen Peng; Talia Henkle; Yung-Nien Chang; Chien-Fu Hung; T-C Wu
Journal:  Cancer Immunol Res       Date:  2018-01-23       Impact factor: 11.151

4.  Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.

Authors:  Rupali Das; Peng Guan; Susan J Wiener; Nishant P Patel; Trevor G Gohl; Elizabeth Evans; Maurice Zauderer; Kim E Nichols
Journal:  Blood Adv       Date:  2019-03-12

Review 5.  Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment.

Authors:  Gloria Delfanti; Paolo Dellabona; Giulia Casorati; Maya Fedeli
Journal:  Front Med (Lausanne)       Date:  2022-05-09

Review 6.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

Review 7.  Invariant natural killer T cells balance B cell immunity.

Authors:  Elizabeth A Leadbetter; Mikael C I Karlsson
Journal:  Immunol Rev       Date:  2021-01-12       Impact factor: 12.988

Review 8.  Natural Killer T Cells in Cancer Immunotherapy.

Authors:  Shiny Nair; Madhav V Dhodapkar
Journal:  Front Immunol       Date:  2017-09-22       Impact factor: 7.561

Review 9.  Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.

Authors:  Reem Ghinnagow; Luis Javier Cruz; Elodie Macho-Fernandez; Christelle Faveeuw; François Trottein
Journal:  Front Immunol       Date:  2017-07-27       Impact factor: 7.561

Review 10.  Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy.

Authors:  Melissa Bedard; Mariolina Salio; Vincenzo Cerundolo
Journal:  Front Immunol       Date:  2017-12-18       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.